Presented by a member of Roche Diagnostics Medical and Scientific Affairs, Roche Diagnostics Corporation, Indianapolis, IN
The presentation provides an overview of: the relevance of PD-L1 as a cancer biomarker,the difference between the FDA classification of Complementary vs Companion Diagnostics, Targeted Therapy vs. Immunotherapy, Current FDA approved PD-L1 IHC assays and indications for use & scoring, Current FDA approved anti-PD1/anti-PD-L1 immunotherapies, Immunotherapy Clinical trial data
2017 Laboratory Webinar Series
Earn CEU's - One contact hour per attendee per session
Group Learning - Unlimited # of participants for one low fee
Archive Sessions - Archived materials are available for 2 years to train new staff
Affordable Education - Order the 12 month series for only $1595.00 by
January 24, 2017. A savings of over $200.00!
$150.00 Per Session: includes all materials, login instructions, archived recordings, and contact hours.
*Please note you may not use the purchased login information at multiple locations of your organization. Only one site may use the login for the live event. If you have additional sites interested in a webinar, they must register.